OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Total Equity

Last Annual Value

56.18M

3-Year CAGR

45%

5-Year CAGR

27%

10-Year CAGR

13%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Total Equity

OKUR · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
56.18M
N/A-17.5%N/A 
9.25M
-29.3%-31.9%-20.3%
70.07M
-28.0%-18.7%N/A
53.55M
-16.5%-21.9%N/A
12.87M
-0.9%-25.6%N/A
35.27M
-1.4%-28.2%N/A
32.76M
-3.4%-14.9%6.2%
-9.51M
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47